We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Radius Health has a disappointing track record. The company has reported wider-than-expected loss in the trailing four trailing quarters with an average negative earnings surprise of 8.93%.
In the last reported quarter, increase in general and administrative expenses led to the wider than anticipated net loss year over year.
Radius Health’s shares have lost 11.1% over a year as against the industry’s 3.1% gain.
Let’s see how things are shaping up for the quarter under review.
Factors at Play
Radius Health develops therapeutics for the treatment of osteoporosis, oncology and endocrine diseases.
The company’s lead drug, Tymlos, was approved in the United States in April 2017. The drug was approved for treating postmenopausal women with osteoporosis at high risk for fracture, defined as history of osteoporotic fracture and multiple risk factors for fracture. The drug can also be used for patients who have failed or are intolerant to other available osteoporosis therapies.The company reported sales of Tymlos (abaloparatide) of $7.7 million in fourth-quarter 2017.
Hence, we expect investors to focus on the uptake of the drug during the upcoming earnings call.
Although the osteoporosis market in the United States has great potential as approximately 1.4 million postmenopausal women suffer from osteoporotic fractures each year, Tymlos is expected to face significant competition from Eli Lilly &Co's LLY Forteo and Amgen’s AMGN Prolia.
Meanwhile, the company’s Marketing Authorisation Application for Eladynos (abaloparatide-SC) in Europe for the treatment of postmenopausal women with osteoporosis was under review. However, the scientific committee of the European Commission, Committee for Medicinal Products for Human Use (“CHMP”), gave a negative trend vote on the benefit-risk balance for the marketing authorization application (“MAA”) for abaloparatide-SC in an oral explanation. The CHMP will therefore adopt a negative opinion on the same. The company was planning to get abaloparatide-SC approved for the treatment of osteoporosis in postmenopausal women at increased risk for fracture. Radius Health plans to seek a re-examination of the CHMP opinion.
In December 2017, the CHMP issued a third Day-180 List of Outstanding Issues and informed the company that it intends to refer the MAA to a scientific advisory group for additional advice. The company has earlier issued a second Day-180 List of Outstanding Issues. The delay in getting approval in Europe is disappointing given the market potential.
Meanwhile, the company presented positive data on elacestrant for breast cancer in December 2017. The FDA also granted Fast Track designation to elacestrant in October 2017. In February 2018, Radius Health obtained scientific advice from the EMA regarding a potential single-arm monotherapy phase II trial of elacestrant in patients with ER-positive/HER2-negative advanced or metastatic breast cancer. Based on feedback from the EMA and the FDA, the company will conduct a single, randomized, controlled phase II trial of elacestrant as a third-line monotherapy in approximately 300 patients with ER positive/HER2 negative advanced/metastatic breast cancer. Hence, we expect the management to throw more light on pipeline progress.
Earnings Whispers
Our proven model does not show that Radius Health is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here, as you will see below.
Zacks ESP: Earnings ESP for Radius Health is currently pegged at +2.42%. This is because the Most Accurate estimate is pegged at a loss of $1.37 while the Zacks Consensus Estimate stands at a loss of $1.40. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Radius Health has a Zacks Rank #4 (Sell). Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement.
Stock to Consider
Here is a pharma company that you may consider, as our model shows that it has the right combination of elements to deliver an earnings beat this quarter.
GW Pharmaceuticals plc is expected to report quarterly results on May 8. The company has an Earnings ESP of +8.11% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
What's in Store for Radius Health (RDUS) in Q1 Earnings?
Radius Health, Inc. (RDUS - Free Report) is scheduled to report first-quarter 2018 results on May 10.
Radius Health, Inc. Price, Consensus and EPS Surprise
Radius Health, Inc. Price, Consensus and EPS Surprise | Radius Health, Inc. Quote
Radius Health has a disappointing track record. The company has reported wider-than-expected loss in the trailing four trailing quarters with an average negative earnings surprise of 8.93%.
In the last reported quarter, increase in general and administrative expenses led to the wider than anticipated net loss year over year.
Radius Health’s shares have lost 11.1% over a year as against the industry’s 3.1% gain.
Let’s see how things are shaping up for the quarter under review.
Factors at Play
Radius Health develops therapeutics for the treatment of osteoporosis, oncology and endocrine diseases.
The company’s lead drug, Tymlos, was approved in the United States in April 2017. The drug was approved for treating postmenopausal women with osteoporosis at high risk for fracture, defined as history of osteoporotic fracture and multiple risk factors for fracture. The drug can also be used for patients who have failed or are intolerant to other available osteoporosis therapies.The company reported sales of Tymlos (abaloparatide) of $7.7 million in fourth-quarter 2017.
Hence, we expect investors to focus on the uptake of the drug during the upcoming earnings call.
Although the osteoporosis market in the United States has great potential as approximately 1.4 million postmenopausal women suffer from osteoporotic fractures each year, Tymlos is expected to face significant competition from Eli Lilly &Co's LLY Forteo and Amgen’s AMGN Prolia.
Meanwhile, the company’s Marketing Authorisation Application for Eladynos (abaloparatide-SC) in Europe for the treatment of postmenopausal women with osteoporosis was under review. However, the scientific committee of the European Commission, Committee for Medicinal Products for Human Use (“CHMP”), gave a negative trend vote on the benefit-risk balance for the marketing authorization application (“MAA”) for abaloparatide-SC in an oral explanation. The CHMP will therefore adopt a negative opinion on the same. The company was planning to get abaloparatide-SC approved for the treatment of osteoporosis in postmenopausal women at increased risk for fracture. Radius Health plans to seek a re-examination of the CHMP opinion.
In December 2017, the CHMP issued a third Day-180 List of Outstanding Issues and informed the company that it intends to refer the MAA to a scientific advisory group for additional advice. The company has earlier issued a second Day-180 List of Outstanding Issues. The delay in getting approval in Europe is disappointing given the market potential.
Meanwhile, the company presented positive data on elacestrant for breast cancer in December 2017. The FDA also granted Fast Track designation to elacestrant in October 2017. In February 2018, Radius Health obtained scientific advice from the EMA regarding a potential single-arm monotherapy phase II trial of elacestrant in patients with ER-positive/HER2-negative advanced or metastatic breast cancer. Based on feedback from the EMA and the FDA, the company will conduct a single, randomized, controlled phase II trial of elacestrant as a third-line monotherapy in approximately 300 patients with ER positive/HER2 negative advanced/metastatic breast cancer. Hence, we expect the management to throw more light on pipeline progress.
Earnings Whispers
Our proven model does not show that Radius Health is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here, as you will see below.
Zacks ESP: Earnings ESP for Radius Health is currently pegged at +2.42%. This is because the Most Accurate estimate is pegged at a loss of $1.37 while the Zacks Consensus Estimate stands at a loss of $1.40. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Radius Health has a Zacks Rank #4 (Sell). Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement.
Stock to Consider
Here is a pharma company that you may consider, as our model shows that it has the right combination of elements to deliver an earnings beat this quarter.
GW Pharmaceuticals plc is expected to report quarterly results on May 8. The company has an Earnings ESP of +8.11% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>